DDInter909 DDInter1840
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Imatinib {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Imatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Imatinib {u} (Compound) binds {v} (Gene) ABL2
ABL2 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Imatinib {u} (Compound) upregulates {v} (Gene) NR1H2
NR1H2 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Bosutinib
Bosutinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Imatinib {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Dasatinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Bosutinib
Bosutinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Imatinib (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Imatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Imatinib (Compound) binds ABL2 (Gene) and ABL2 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Imatinib (Compound) upregulates NR1H2 (Gene) and NR1H2 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Imatinib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Imatinib (Compound) resembles Ponatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Imatinib may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)